Actualités de la communauté

04.04.2016 Anergis Closes CHF 5 Million Financing Round Extension to Conduct the ATIBAR Trial

Anergis Closes CHF 5 Million Financing Round Extension to Conduct Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT.

> Communiqué de presse Anergis (en anglais)

retour